Ординатура / Офтальмология / Английские материалы / Retinal Degenerations biology, diagnostics, and therapeutics_Tombran-Tink, Barnstable_2007

161.Mitchell P, Wang JJ, Smith W, Leeder SR. Smoking and the 5-year incidence of agerelated maculopathy: the Blue Mountains Eye Study. Arch Ophthalmol 2002;120: 1357–1363.

162.Klein R, Klein BE, Moss SE. Relation of smoking to the incidence of age-related maculopathy. The Beaver Dam Eye Study. Am J Epidemiol 1998;147:103–110.

163.Klein R, Klein BE, Tomany SC, Moss SE. Ten-year incidence of age-related maculopathy and smoking and drinking: the Beaver Dam Eye Study. Am J Epidemiol 2002;156: 589–598.

164.Kelly SP, Edwards R, Elton P, Mitchell P. Age related macular degeneration: smoking entails major risk of blindness. BMJ 2003;326:1458–1459.

165.Suner IJ, Espinosa-Heidmann DG, Marin-Castano ME, Hernandez EP, Pereira-Simon S, Cousins SW. Nicotine increases size and severity of experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2004;45:311–317.

166.Chan D. Cigarette smoking and age-related macular degeneration. Optom. Vis Sci 1998;75:476–484.

167.DeBlack SS. Cigarette smoking as a risk factor for cataract and age-related macular degeneration: a review of the literature. Optometry 2003;74:99–110.

168.Mitchell P, Chapman S, Smith W. “Smoking is a major cause of blindness”: a new cigarette pack warning? Med J Aust 1999;171:173–174.

169.Schwartz D. The Beaver Dam Eye Study: the relation of age-related maculopathy to smoking. Surv Ophthalmol 1994;39:84–85.

170.Obisesan TO, Hirsch R, Kosoko O, Carlson L, Parrott M. Moderate wine consumption is associated with decreased odds of developing age-related macular degeneration in NHANES–1. J Am Geriatr Soc 1998;46:1–7.

171.Ritter LL, Klein R, Klein BE, Mares Perlman JA, Jensen SC. Alcohol use and age-related maculopathy in the Beaver Dam Eye Study. Am J Ophthalmol 1995;120:190–196.

172.Smith W. Mitchell P. Alcohol intake and age-related maculopathy. Am J Ophthalmol 1996;122:743–745.

173.Moss SE, Klein R, Klein BE, Jensen SC, Meuer SM. Alcohol consumption and the 5-year incidence of age-related maculopathy: the Beaver Dam eye study. Ophthalmology 1998;105:789–794.

174.Ajani UA, Christen WG, Manson JE, et al. A prospective study of alcohol consumption and the risk of age-related macular degeneration. Ann Epidemiol 1999;9:172–177.

175.Cho E, Hankinson SE, Willett WC, et al. Prospective study of alcohol consumption and the risk of age-related macular degeneration. Arch Ophthalmol 2000;118:681–688.

176.Sarma U, Brunner E, Evans J, Wormald R. Nutrition and the epidemiology of cataract and age-related maculopathy. Eur J Clin Nutr 1994;48:1–8.

177.Winkler BS, Boulton ME, Gottsch JD, Sternberg P. Oxidative damage and age-related macular degeneration. Mol Vis 1999;5:32.

178.Gu X, Meer SG, Miyagi M, et al. Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J Biol Chem 2003;278:42,027–42,035.

179.Seddon JM, Ajani UA, Sperduto RD, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group [see comments]. J Am Med Assoc 1994;272:1413–1420.

180.Pratt S. Dietary prevention of age-related macular degeneration. J Am Optom Assoc 1999;70:39–47.

181.Beatty S, Murray IJ, Henson DB, Carden D, Koh H, Boulton ME. Macular pigment and risk for age-related macular degeneration in subjects from a Northern European population. Invest Ophthalmol Vis Sci 2001;42:439–446.

182.Horowitz S. Lutein update: protecting the eyes and the heart with the yellow carotenoid. Alt Comp Ther 2000;6:272–277.

183.Eye Disease Case-Control Study Group. Antioxidant status and neovascular age-related macular degeneration. Arch Ophthalmol 1993;111:104–109.

184.Snellen EL, Verbeek AL, Van Den Hoogen GW, Cruysberg JR, Hoyng CB. Neovascular age-related macular degeneration and its relationship to antioxidant intake. Acta Ophthalmol Scand 2002;80:368–371.

185.Gale CR, Hall NF, Phillips DI, Martyn CN. Lutein and zeaxanthin status and risk of agerelated macular degeneration. Invest Ophthalmol Vis Sci 2003;44:2461–2465.

186.De La Paz MA, Zhang J, Fridovich I. Red blood cell antioxidant enzymes in age-related macular degeneration. Br J Ophthalmol 1996;80:445–450.

187.Goldberg J, Flowerdew G, Smith E, Brody J, Tso M. Factors associated with age-related macular degeneration. An analysis of data from the first National Health and Nutrition Survey. Am J Epidemiol 1988;128:700–710.

188.Vaicaitiene R, Luksiene DK, Paunksnis A, Cerniauskiene LR, Domarkiene S, Cimbalas A. Age-related maculopathy and consumption of fresh vegetables and fruits in urban elderly. Medicina (Kaunas) 2003;39:1231–1236.

189.Cho E, Seddon JM, Rosner B, Willett WC, Hankinson SE. Prospective study of intake of fruits, vegetables, vitamins, and carotenoids and risk of age-related maculopathy. Arch Ophthalmol 2004;122:883–892.

190.Seddon JM, Hennekens CH. Vitamins, minerals, and macular degeneration. Promising but unproven hypotheses [editorial]. Arch Ophthalmol 1994;112:176–179.

191.Cooper DA, Eldridge AL, Peters JC. Dietary carotenoids and certain cancers, heart disease, and age-related macular degeneration: a review of recent research. Nutr Rev 1999;57:201–214.

192.West S, Vitale S, Hallfrisc J, et al. Are antioxidants or supplements protective for agerelated macular degeneration? Arch Ophthalmol 1994;112:222–227.

193.Mares-Perlman JA, Brady WE, Klein R, et al. Serum antioxidants and age-related macular degeneration in a population-based case-control study. Arch Ophthalmol 1995;113:1518–1523.

194.Smith W, Mitchell P, Rochester C. Serum beta carotene, alpha tocopherol, and age-related maculopathy: the Blue Mountains Eye Study. Am J Ophthalmol 1997;124:838–840.

195.Mares-Perlman JA, Fisher AI, Klein R, et al. Lutein and Zeaxanthin in the Diet and Serum and Their Relation to Age-Related Maculopathy in the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2001;153:424–432.

196.Mares-Perlman JA, Klein R, Klein BE, et al. Association of zinc and antioxidant nutrients with age-related maculopathy. Arch Ophthalmol 1996;114:991–997.

197.Smith W, Mitchell P, Webb K, Leeder SR. Dietary antioxidants and age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology 1999;106:761–767.

198.Kuzniarz M, Mitchell P, Flood VM, Wang JJ. Use of vitamin and zinc supplements and age-related maculopathy: the Blue Mountains Eye Study. Ophthalmic Epidemiol 2002;9:283–295.

199.Delcourt C, Cristol JP, Tessier F, Leger CL, Descomps B, Papoz L. Age-related macular degeneration and antioxidant status in the POLA study. POLA Study Group. Pathologies Oculaires Liees al’Age. Arch Ophthalmol 1999;117:1384–1390.

200.Delcourt C, Cristol JP, Leger CL, Descomps B, Papoz L. Associations of antioxidant enzymes with cataract and age-related macular degeneration. The POLA Study. Pathologies Oculaires Liees al’Age. Ophthalmology 1999;106:215–222.

201.VandenLangenberg GM, Mares Perlman JA, Klein R, Klein BE, Brady WE, Palta M. Associations between antioxidant and zinc intake and the 5-year incidence of early agerelated maculopathy in the Beaver Dam Eye Study. Am J Epidemiol 1998;148:204–214.

202.Christen WG, Ajani UA, Glynn RJ, et al. Prospective cohort study of antioxidant vitamin supplement use and the risk of age-related maculopathy. Am J Epidemiol 1999;149:476–484.

203.Cho E, Stampfer MJ, Seddon JM, et al. Prospective study of zinc intake and the risk of age-related macular degeneration. Ann Epidemiol 2001;11:328–336.

204.Flood V, Smith W, Wang JJ, Manzi F, Webb K, Mitchell P. Dietary antioxidant intake and incidence of early age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology 2002;109:2272–2278.

205.Evans JR. Antioxidant vitamin and mineral supplements for age-related macular degeneration. Cochrane Database Syst Rev 2002;volume 2.

206.Richer S. Multicenter ophthalmic and nutritional age-related macular degeneration study— part 2: antioxidant intervention and conclusions. J Am Optom Assoc 1996;67:30–49.

207.Stur M, Tittl M, Reitner A, Meisinger V. Oral zinc and the second eye in age-related macular degeneration. Invest Ophthalmol Vis Sci 1996;37:1225–1235.

208.Teikari JM, Laatikainen L, Virtamo J, et al. Six-year supplementation with alpha-toco- pherol and beta-carotene and age-related maculopathy. Acta Ophthalmol Scand 1998; 76:224–229.

209.Richer S, Stiles W, Statkute L, et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 2004;75:216–230.

210.Koh HH, Murray IJ, Nolan D, Carden D, Feather J, Beatty S. Plasma and macular responses to lutein supplement in subjects with and without age-related maculopathy: a pilot study. Exp Eye Res 2004;79:21–27.

211.Seigel D. AREDS investigators distort findings. Arch Ophthalmol 2002;120:100–101.

212.Ambati J, Ambati BK. Age-related eye disease study caveats. Arch Ophthalmol 2002;120:997–999.

213.Tomany SC, Klein R, Klein BE. The relation of coffee and caffeine to the 5-year incidence of early age-related maculopathy: the Beaver Dam Eye Study. Am J Ophthalmol 2001;132:271–273.

214.Seddon JM, Cote J, Rosner B. Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake. Arch Ophthalmol 2003;121:1728–1737.

215.Mares-Perlman JA, Brady WE, Klein R, VandenLangenberg GM, Klein BE, Palta M. Dietary fat and age-related maculopathy. Arch Ophthalmol 1995;113:743–748.

216.Friedman E. Dietary fat and age-related maculopathy [letter]. Arch Ophthalmol 1996;114:235–236.

217.Cho E, Hung S, Willett WC, Spiegelman D, et al. Prospective study of dietary fat and the risk of age-related macular degeneration. Am J Clin Nutr 2001;73:209–218.

218.Snow KK, Seddon JM. Do age-related macular degeneration and cardiovascular disease share common antecedents? Ophthalmic Epidemiol 1999;6:125–143.

219.Espinosa-Heidmann DG, Sall J, Hernandez EP, Cousins SW. Basal laminar deposit formation in APO B100 transgenic mice: complex interactions between dietary fat, blue light, and vitamin E. Invest Ophthalmol Vis Sci 2004;45:260–266.

220.Sarks JP, Sarks SH, Killingsworth MC. Evolution of soft drusen in age-related macular degeneration. Eye 1994;8:269–283.

221.Sanders TA, Haines AP, Wormald R, Wright LA, Obeid O. Essential fatty acids, plasma cholesterol, and fat-soluble vitamins in subjects with age-related maculopathy and matched control subjects. Am J Clin Nutr 1993;57:428–433.

222.Smith W, Mitchell P, Leeder SR. Dietary fat and fish intake and age-related maculopathy. Arch Ophthalmol 2000;118:401–404.

223.Heuberger RA, Mares-Perlman JA, Klein R, Klein BE, Millen AE, Palta M. Relationship of dietary fat to age-related maculopathy in the Third National Health and Nutrition Examination Survey. Arch Ophthalmol 2001;119:1833–1838.

224.Seddon JM, Rosner B, Sperduto RD, et al. Dietary fat and risk for advanced age-related macular degeneration. Arch Ophthalmol 2001;119:1191–1199.

225.McGwin G Jr., Owsley C, Curcio CA, Crain RJ. The association between statin use and age related maculopathy. Br J Ophthalmol 2003;87:1121–1125.

226.Wilson HL, Schwartz DM, Bhatt HR, McCulloch CE, Duncan JL. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol 2004;137:615–624.

227.McCarty CA, Mukesh BN, Guymer RH, Baird PN, Taylor HR. Cholesterol-lowering medications reduce the risk of age-related maculopathy progression. Med J Aust 2001; 175:340.

228.Klein R, Klein BE, Tomany SC, Danforth LG, Cruickshanks KJ. Relation of statin use to the 5-year incidence and progression of age-related maculopathy. Arch Ophthalmol 2003;121:1151–1155.

229.Klein R, Klein BE, Jensen SC, et al. Medication use and the five-year incidence of early age-related maculopathy: the Beaver Dam Eye Study. Arch Ophthalmol 2001; 119:1354–1359.

230.van Leeuwen R, Vingerling JR, Hofman A, de Jong PT, Stricker BH. Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement. BMJ 2003;326:255–256.

231.Holz FG, Piguet B, Minassian DC, Bird AC, Weale RA. Decreasing stromal iris pigmentation as a risk factor for agerelated macular degeneration. Am J Ophthalmol 1994;117:19–23.

232.Chaine G, Hullo A, Sahel J, et al. Case-control study of the risk factors for age related macular degeneration. France-DMLA Study Group. Br J Ophthalmol 1998;82:996–1002.

233.Sandberg MA, Gaudio AR, Miller S, Weiner A. Iris pigmentation and extent of disease in patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 1994;35:2734–2740.

234.Vinding T. Pigmentation of the eye and hair in relation to age-related macular degeneration. An epidemiological study of 1000 aged individuals. Acta Ophthalmol Copenh 1990;6:53–58.

235.Mitchell P, Smith W, Wang JJ. Iris color, skin sun sensitivity, and age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology 1998;105:1359–1363.

236.Klein R, Klein BE, Jensen SC, Cruickshanks KJ. The relationship of ocular factors to the incidence and progression of age-related maculopathy. Arch Ophthalmol 1998;116:506–513.

237.Wang JJ, Jakobsen K, Smith W, Mitchell P. Five-year incidence of age-related maculopathy in relation to iris, skin or hair colour, and skin sun sensitivity: the Blue Mountains Eye Study. Clin Experiment Ophthalmol 2003;31:317–321.

238.Tomany SC, Klein R, Klein BE. The relationship between iris color, hair color, and skin sun sensitivity and the 10-year incidence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 2003;110:1526–1533.

239.Darzins P, Mitchell P, Heller RF. Sun exposure and age-related macular degeneration. An Australian case-control study. Ophthalmology 1997;104:770–776.

240.Berendschot T, Willemse-Assink JJ, Bastiaanse M, de Jong PT, van Norren D. Macular pigment and melanin in age-related maculopathy in a general population. Invest Ophthalmol Vis Sci 2002;43:1928–1932.

241.Taylor HR, Munoz B, West S, Bressler NM, Bressler SB, Rosenthal FS. Visible light and risk of age-related macular degeneration. Trans Am Ophthalmol Soc 1990;88:163–173.

242.Cruickshanks KJ, Klein R, Klein BE. Sunlight and age-related macular degeneration: the Beaver Dam Eye Study. Arch Ophthalmol 1993;111:514–518.

243.Delcourt C, Carriere I, Ponton-Sanchez A, Fourrey S, Lacroux A, Papoz L. Light exposure and the risk of age-related macular degeneration: the Pathologies Oculaires Liees al’Age (POLA) study. Arch Ophthalmol 2001;119:1463–1468.

244.Pham TQ, Wang JJ, Rochtchina E, Mitchell P. Pterygium/pinguecula and the five-year incidence of age-related maculopathy. Am J Ophthalmol 2005;139:536–537.

245.West SK, Rosenthal FS, Bressler NM, et al. Exposure to sunlight and other risk factors for age-related macular degeneration. Arch Ophthalmol 1989;107:875–879.

246.Cruickshanks KJ, Klein R, Klein BE, Nondahl DM. Sunlight and the 5-year incidence of early age-related maculopathy: the Beaver Dam Eye Study. Arch Ophthalmol 2001; 119:246–250.

247.Tomany SC, Cruickshanks KJ, Klein R, Klein BE, Knudtson MD. Sunlight and the 10year incidence of age-related maculopathy: the Beaver Dam Eye Study. Arch Ophthalmol 2004;122:750–757.

248.Hirvela H, Luukinen H, Laara E, Sc L, Laatikainen L. Risk factors of age-related maculopathy in a population 70 years of age or older. Ophthalmology 1996;103:871–877.

249.Miyazaki M, Nakamura H, Kubo M, et al. Risk factors for age related maculopathy in a Japanese population: the Hisayama study. Br J Ophthalmol 2003;87:469–472.

250.Marin-Castano ME, Elliot SJ, Potier M, et al. Regulation of estrogen receptors and MMP–2 expression by estrogens in human retinal pigment epithelium. Invest Ophthalmol Vis Sci 2003;44:50–59.

251.Espinosa-Heidmann DG, Marin-Castano ME, Pereira-Simon S, Hernandez EP, Elliot S, Cousins SW. Gender and estrogen supplementation increases severity of experimental choroidal neovascularization. Exp Eye Res 2005;80:413–423.

252.Vingerling JR, Dielemans I, Witteman JC, Hofman A, Grobbee DE, de Jong PT. Macular degeneration and early menopause: a case-control study. BMJ 1995;310: 1570–1571.

253.Smith W, Mitchell P, Wang JJ. Gender, oestrogen, hormone replacement and age-related macular degeneration: results from the Blue Mountains Eye Study. Aust New Zealand J Ophthalmol 1997;25 Suppl 1:S13–S15.

254.Klein BE, Klein R, Jensen SC, Ritter LL. Are sex hormones associated with age-related maculopathy in women? The Beaver Dam Eye Study. Trans Am Ophthalmol Soc 1994;92:289–295.

255.Defay R, Pinchinat S, Lumbroso S, Sutan C, Delcourt C. Sex steroids and age-related macular degeneration in older French women: the POLA study. Ann Epidemiol 2004;14:202–208.

256.Klein BE, Klein R, Lee KE. Reproductive exposures, incident age-related cataracts, and age-related maculopathy in women: the beaver dam eye study. Am J Ophthalmol 2000; 130:322–326.

257.Snow KK, Cote J, Yang W, Davis NJ, Seddon JM. Association between reproductive and hormonal factors and age-related maculopathy in postmenopausal women. Am J Ophthalmol 2002;134:842–848.

258.Abramov Y, Borik S, Yahalom C, et al. The effect of hormone therapy on the risk for agerelated maculopathy in postmenopausal women. Menopause 2004;11:62–68.

259.Rulon LL, Robertson JD, Lovell MA, Deibel MA, Ehmann WD, Markesber WR. Serum zinc levels and Alzheimer’s disease. Biol Trace Elem Res 2000;75:79–85.

260.Klein R, Klein BE, Jensen SC, Moss SE, Cruickshanks KJ. The relation of socioeconomic factors to age-related cataract, maculopathy, and impaired vision: the Beaver Dam Eye Study. Ophthalmology 1994;101:1969–1979.

261.Klein R, Klein BE, Jensen SC, Moss SE. The relation of socioeconomic factors to the incidence of early age-related maculopathy: the Beaver Dam Eye Study. Am J Ophthalmol 2001;132:128–131.

262.Huang GH, Klein R, Klein BE, Tomany SC. Birth cohort effect on prevalence of age-related maculopathy in the Beaver Dam Eye Study. Am J Epidemiol 2003;157: 721–729.

263.Vingerling JR, Dielemans I, Bots ML, Hofman A, Grobbee DE, de Jong PT. Age-related macular degeneration is associated with atherosclerosis. The Rotterdam Study. Am J Epidemiol 1995;142:404–409.

264.Sperduto RD, Hiller R. Systemic hypertension and age-related maculopathy in the Framingham Study. Arch Ophthalmol 1986;104:216–219.

265.Hyman L, Schachat AP, He Q, Leske MC. Hypertension, cardiovascular disease, and agerelated macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. Arch Ophthalmol 2000;118:351–358.

266.Smith W, Mitchell P, Leeder SR, Wang JJ. Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: the Blue Mountains Eye Study. Arch Ophthalmol 1998;116:583–587.

267.Delcourt C, Michel F, Colvez A, Lacroux A, Delage M, Vernet MH. Associations of cardiovascular disease and its risk factors with age-related macular degeneration: the POLA study. Ophthalmic Epidemiol 2001;8:237–249.

268.Klein R, Klein BE, Franke T. The relationship of cardiovascular disease and its risk factors to age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1993;100:406–414.

269.Schaumberg DA, Christen WG, Hankinson SE, Glynn RJ. Body mass index and the incidence of visually significant age-related maculopathy in men. Arch Ophthalmol 2001;119:1259–1265.

270.Seddon JM, Cote J, Davis N, Rosner B. Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol 2003;121:785–792.

271.Klein R, Klein BE, Jensen SC. The relation of cardiovascular disease and its risk factors to the 5-year incidence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1997;104:1804–1812.

272.Klein R, Klein BEK, Tomany SC, Cruickshanks KJ. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 2003;110:1273–1280.

273.van Leeuwen R, Ikram MK, Vingerling JR, Witteman JC, Hofman A, de Jong PT. Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci 2003;44:3771–3777.

274.Wang JJ, Mitchell P, Rochtchina E, Tan AG, Wong TY, Klein R. Retinal vessel wall signs and the 5-year incidence of age related maculopathy: the Blue Mountains Eye Study. Br J Ophthalmol 2004;88:104–109.

275.van Leeuwen R, Klaver CC, Vingerling JR, et al. Cholesterol and age-related macular degeneration: is there a link? Am J Ophthalmol 2004;137:750–752.

276.Voutilainen-Kaunisto RM, Terasvirta ME, Uusitupa MI, Niskanen LK. Age-related macular degeneration in newly diagnosed type 2 diabetic patients and control subjects: a 10-year follow-up on evolution, risk factors, and prognostic significance. Diabetes Care 2000; 23:1672–1678.

277.Clemons TE, Kurinij N, Sperduto RD. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study: AREDS Report No. 13. Arch Ophthalmol 2004;122:716–726.

278.Wu KH, Wang JJ, Rochtchina E, Foran S, Ng MK, Mitchell P. Angiotensin-converting enzyme inhibitors (ACEIs) and age-related maculopathy (ARM): cross-sectional findings from the Blue Mountains Eye Study. Acta Ophthalmol Scand 2004;82:298–303.

279.Christen WG, Glynn RJ, Ajani UA, et al. Age-related maculopathy in a randomized trial of low-dose aspirin among US physicians. Arch Ophthalmol 2001;119:1143–1149.

280.Penfold PL, Provis JM, Billson FA. Age-related macular degeneration: ultrastructural studies of the relationship of leucocytes to angiogenesis. Graefes Arch Clin Exp Ophthalmol 1987;225:70–76.

281.Espinosa-Heidmann DG, Suner IJ, Hernandez EP, Monroy D, Csaky KG, Cousins SW. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44:3586–3592.

282.Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999;340:115–126.

283.Margolis TP, Lietman T, Strauss E. Infectious agents and ARMD: a connection? Am J Ophthalmol 2004;138:468–470.

284.Klein R, Klein BE, Tomany SC, Cruickshanks J. Association of emphysema, gout, and inflammatory markers with long-term incidence of age-related maculopathy. Arch Ophthalmol 2003;121:674–678.

285.Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N. Association between C-reactive protein and age-related macular degeneration. JAMA 2004;291:704–710.

286.Kalayoglu MV, Galvan C, Mahdi OS, Byrne GI, Mansour S. Serological association between Chlamydia pneumoniae infection and age-related macular degeneration. Arch Ophthalmol 2003;121:478–482.

287.Miller DM, Espinosa-Heidmann DG, Legra J, et al. The association of prior cytomegalovirus infection with neovascular age-related macular degeneration. Am J Ophthalmol 2004;138:323–328.

288.Cousins SW, Espinosa-Heidmann DG, Csaky KG. Monocyte activation in patients with age-related macular degeneration: a biomarker of risk for choroidal neovascularization? Arch Ophthalmol 2004;122:1013–1018.

289.Ishida O, Oku H, Ikeda T, Nishimura M, Kawagoe K, Nakamura K. Is Chlamydia pneumoniae infection a risk factor for age related macular degeneration? Br J Ophthalmol 2003;87:523–524.

290.Wang JJ, Mitchell P, Smith W, Gillies M, Billson F. Systemic use of anti-inflammatory medications and age-related maculopathy: the Blue Mountains Eye Study. Ophthalmic Epidemiol 2003;10:37–48.

291.Klein R, Klein BE, Moss SE. Diabetes, hyperglycemia, and age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1992;99:1527–1534.

292.Mitchell P, Wang JJ. Diabetes, fasting blood glucose and age-related maculopathy: The Blue Mountains Eye Study. Aust New Zealand J Ophthalmol 1999;27:197–199.

293.Sperduto RD, Hiller R, Seigel D. Lens opacities and senile maculopathy. Arch Ophthalmol 1981;99:1004–1008.

294.Liu IY, White L, LaCroix AZ. The association of age-related macular degeneration and lens opacities in the aged. Am J Public Health 1989;79:765–769.

295.Klein R, Klein BE, Wang Q, Moss SE. Is age-related maculopathy associated with cataracts? Arch Ophthalmol 1994;112:191–196.

296.Wang JJ, Mitchell PG, Cumming RG, Lim R. Cataract and age-related maculopathy: the Blue Mountains Eye Study. Ophthalmic Epidemiol 1999;6:317–326.

297.Oliver M. Posterior pole changes after cataract extraction in elderly subjects. Am J Ophthalmol 1966;62:1145–1148.

298.Blair CJ, Ferguson J, Jr. Exacerbation of senile macular degeneration following cataract extraction. Am J Ophthalmol 1979;87:77–83.

299.Klein BE, Klein R, Moss SE. Exogenous estrogen exposures and changes in diabetic retinopathy. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 1999;22:1984–1987.

300.van der Schaft TL, Mooy CM, de Bruijn WC, Mulder PG, Pameyer JH, de Jong PT. Increased prevalence of disciform macular degeneration after cataract extraction with implantation of an intraocular lens. Br J Ophthalmol 1994;78:441–445.

301.Pollack A, Marcovich A, Bukelman A, Oliver M. Age-related macular degeneration after extracapsular cataract extraction with intraocular lens implantation. Ophthalmology 1996;103:1546–1554.

302.Pollack A, Marcovich A, Bukelman A, Zalish M, Oliver M. Development of exudative age-related macular degeneration after cataract surgery. Eye 1997;11:523–530.

303.Armbrecht AM, Findlay C, Aspinall PA, Hill AR, Dhillon B. Cataract surgery in patients with age-related macular degeneration: one-year outcomes. J Cataract Refract Surg 2003;29:686–693.

304.Klein R, Klein BE, Wong TY, Tomany SC, Cruickshanks KJ. The association of cataract and cataract surgery with the long-term incidence of age-related maculopathy: the Beaver Dam eye study. Arch Ophthalmol 2002;120:1551–1558.

305.Klein BE, Klein R, Moss SE. Incident cataract surgery: the Beaver Dam Eye Study. Ophthalmology 1997;104:573–580.

306.Wang JJ, Klein R, Smith W, Klein BEK, Tomany S, Mitchell P. Cataract surgery and the 5-year incidence of age-related macular degeneration: Pooled findings from the Beaver Dam and Blue Mountains Eye Studies. Ophthalmology 2003;110:1960–1967.

307.Tan AG, Wang JJ, Rochtchina E, Jakobsen K, Mitchell P. Increase in cataract surgery prevalence from 1992–1994 to 1997–2000: analysis of two population cross-sections. Clin Experiment Ophthalmol 2004;32:284–288.

308.Boker T, Fang T, Steinmetz R. Refractive error and choroidal perfusion characteristics in patients with choroidal neovascularization and age-related macular degeneration. Ger J Ophthalmol 1993;2:10–13.

309.Maltzman BA, Mulvihill MN, Greenbaum A. Senile macular degeneration and risk factors: a case-control study. Ann Ophthalmol 1979;11:1197–1201.

310.Sandberg MA, Tolentino MJ, Miller S, Berson EL, Gaudio AR. Hyperopia and neovascularization in age-related macular degeneration. Ophthalmology 1993;100:1009–1013.

311.Wang JJ, Mitchell P, Smith W. Refractive error and age-related maculopathy: the Blue Mountains Eye Study. Invest. Ophthalmol Vis Sci 1998;39:2167–2171.

312.Ikram MK, van Leeuwen R, Vingerling JR, Hofman A, de Jong PT. Relationship between refraction and prevalent as well as incident age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci 2003;44:3778–3782.

313.Wong TY, Klein R, Klein BE, Tomany SC. Refractive errors and 10-year incidence of age-related maculopathy. Invest Ophthalmol Vis Sci 2002;43:2869–2873.

314.Wang JJ, Jakobsen KB, Smith W, Mitchell P. Refractive status and the 5-year incidence of age-related maculopathy: the Blue Mountains Eye Study. Clin Experiment Ophthalmol 2004;32:255–258.

315.Mangione CM, Gutierrez PR, Lowe G, Orav EJ, Seddon JM. Influence of age-related maculopathy on visual functioning and health-related quality of life. Am J Ophthalmol 1999;128:45–53.

316.Foran S, Wang JJ, Mitchell P. Causes of incident visual impairment: the blue mountains eye study. Arch Ophthalmol 2002;120:613–619.

317.Chia EM, Wang JJ, Rochtchina E, Smith W, Cumming RG, Mitchell P. Impact of Bilateral Visual Impairment on Health-Related Quality of Life: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci 2004;45:71–76.

318.Maguire M. Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). Ophthalmology 2004;111:1307–1316.

319.La Forge RG, Spector WD, Sternberg J. The relationship of vision and hearing impairment to one-year mortality and functional decline. J Aging Health 1992;4:126–148.

320.Rudberg MA, Furner SE, Dunn JE, Cassel CK. The relationship of visual and hearing impairments to disability: an analysis using the longitudinal study of aging. J Gerontol 1993;48:M261–M265.

321.Carabellese C, Appollonio I, Rozzini R, et al. Sensory impairment and quality of life in a community elderly population. J Am Geriatr Soc 1993;41:401–407.

322.Salive ME, Guralnik J, Glynn RJ, Christen W, Wallace RB, Ostfeld AM. Association of visual impairment with mobility and physical function. J Am Geriatr Soc 1994;42: 287–292.

323.Rubin GS, Roche KB, Prasada Rao P, Fried LP. Visual impairment and disability in older adults. Optom Vis Sci 1994;71:750–760.

324.Dargent Molina P, Hays M, Breart G. Sensory impairments and physical disability in aged women living at home. Int J Epidemiol 1996;25:621–629.

325.Lee PP, Spritzer K, Hays RD. The impact of blurred vision on functioning and well-being. Ophthalmology 1997;104:390–396.

326.Lee P, Smith JP, Kington R. The relationship of self-rated vision and hearing to functional status and well-being among seniors 70 years and older. Am J Ophthalmol 1999;127: 447–452.

327.Reuben DB, Mui S, Damesyn M, Moore AA, Greendale GA. The prognostic value of sensory impairment in older persons. J Am Geriatr Soc 1999;47:930–935.

328.Harries U, Landes R, Popay J. Visual disability among older people: a case study in assessing needs and examining services. J Public Health Med 1994;16:211–218.

329.Ivers RQ, Cumming RG, Mitchell P, Attebo K. Visual impairment and falls in older adults: the Blue Mountains Eye Study. J Am Geriatr Soc 1998;46:58–64.

330.Ivers R, Cumming R, Mitchell P. Poor vision and risk of falls and fractures in older Australians: the Blue Mountains Eye Study. NSW Public Health Bull 2002;13:8–10.

331.Ivers RQ, Norton R, Cumming RG, Butler M, Campbell AJ. Visual impairment and risk of hip fracture. Am J Epidemiol 2000;152:633–639.

332.Ivers RQ, Optom B, Cumming RG, Mitchell P, Simpson JM, Peduto AJ. Visual risk factors for hip fracture in older people. J Am Geriatr Soc 2003;51:356–363.

333.Brody BL, Gamst AC, Williams RA, et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology 2001;108: 1893–1900.

334.Rovner BW, Casten RJ, Tasman WS. Effect of depression on vision function in age-related macular degeneration. Arch Ophthalmol 2002;120:1041–1044.

335.Casten RJ, Rovner BW, Tasman W. Age-related macular degeneration and depression: a review of recent research. Curr Opin Ophthalmol 2004;15:181–183.

336.Klein R, Cruickshanks KJ, Klein BE, Nondahl DM, Wiley T. Is age-related maculopathy related to hearing loss? Arch Ophthalmol 1998;116:360–365.

337.Klaver CC, Ott A, Hofman A, Assink JJ, Breteler MM, de Jong PT. Is age-related maculopathy associated with Alzheimer’s disease? The Rotterdam Study. Am J Epidemiol. 1999;150:963–968.

338.Wong TY, Klein R, Nieto FJ, et al. Is early age-related maculopathy related to cognitive function? The Atherosclerosis Risk in Communities Study. Am J Ophthalmol 2002;134:828–835.

339.Wang JJ, Mitchell P, Smith W. Vision and low self-rated health: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci 2000;41:49–54.

340.Wang JJ, Mitchell P, Cumming RG, Smith W. Visual impairment and nursing home placement in older Australians: the Blue Mountains Eye Study. Ophthal Epidemiol 2002;10: 3–13.

341.Kleiner RC, Enger C, Alexander MF, Fine SL. Contrast sensitivity in age-related macular degeneration. Arch Ophthalmol 1988;106:55–57.

342.Klein R, Klein BE, Moss SE. Age-related eye disease and survival: the Beaver Dam Eye Study. Arch Ophthalmol 1995;113:333–339.

343.Wang JJ, Mitchell P, Simpson JM, Cumming RG, Smith W. Visual impairment, age-related cataract, and mortality. Arch Ophthalmol 2001;119:1186–1190.

344.Taylor HR, McCarty CA, Nanjan MB. Vision impairment predicts five-year mortality. Trans Am Ophthalmol Soc 2000;98:91–96.

345.Buch H, Vinding T, la Cour M, Jensen GB, Prause JU, Nielsen NV. Age-related maculopathy: a risk indicator for poorer survival in women: the Copenhagen City Eye Study. Ophthalmology 2005;112:305–312.

346.Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol 2003;87:312–317.

347.Hopley C, Carter R, Mitchell P. Measurement of the economic impact of visual impairment from age-related macular degeneration in Australia. Clin Experiment Ophthalmol 2003;31:522–529.

348.Lanchoney DM, Maguire MG, Fine SL. A model of the incidence and consequences of choroidal neovascularization secondary to age-related macular degeneration. Comparative effects of current treatment and potential prophylaxis on visual outcomes in high-risk patients. Arch Ophthalmol 1998;116:1045–1052.

349.Hopley C, Salkeld G, Wang JJ, Mitchell P. Cost utility of screening and treatment for early age-related macular dageneration with zinc and antioxidants. Br J Ophthalmol 2004;88:450–454.

350.Wright AF. Strategies for mapping susceptibility genes in age-related maculopathy. Eye 2001;15:401–406.

351.Thakkinstian A, Bowe S, McEvoy M, Smith W, Attia J. Association between apolipoprotein E polymorphisms and age-related macular degeneration: A HuGE review and metaanalysis. Am J Epidemiol 2006 (in press).

352.Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005;102:7227–7232.

353.Jakobsdottir J, Conely YP, Weeks DE, Mah TS, Ferrell RE, Gorin MB. Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet 2005;77: 389–407.

354.Rivera A, Fisher SA, Fritsche LG et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet 2005;14:3227–3236.

355.Schmidt S, Hauser MA, Scott WK et al. Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration. Am J Hum Genet 2006;78:852–864.

356.Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet 2006;38: 458–462.

357.Haan MN, Klein R, Klein BE, et al. Hormone therapy and age-related macular degeneration: the Women’s Health Initiative Sight Exam Study. Arch Ophthalmol 2006;124:988–992.

358.Klein R, Klein BE, Knudrson MD, Wong TY, Shankar A, Tsai MY. Systemic markers of inflammation, endothelial dysfunction, and age-related maculopathy. Am J Ophthalmol 2005;140:35–44.